IceCure Medical

IceCure is transforming breast cancer care by empowering patients with the choice of minimally invasive cryoablation. As the first and only FDA cleared medical device for the local treatment of breast cancer, the ProSense® System uses advanced liquid-nitrogen technology to generate ultra cold temperatures to destroy breast tumors by freezing them. ProSense® empowers patients with the option of a less invasive, office-based procedure as an option to surgical tumor removal.
ProSense® Cryoablation is indicated for the local treatment of low-risk breast cancer in patients aged 70 and above with endocrine therapy, including those patients not suitable for surgical breast cancer treatment.
The FDA indication was largely based on IceCure’s landmark ICE3 Study, which found ProSense to be safe and effective with a 3.1% IBTR for those patients treated with cryoablation and endocrine therapy. 99.1% of patients and 97% of physicians expressed they were very satisfied or satisfied with the cosmetic outcome of the procedure. Return to routine activity was generally within 24 hours.

ProSense® currently has FDA clearance for use as a cryosurgical tool in the destruction of fibroadenomas and in the fields of general surgery, thoracic surgery, gynecology, oncology, proctology, and urology. The system is CE-marked and is available globally including across Europe, Brazil, and Asia.